Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Keros Therapeutics has raised $140.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2024.
Keros Therapeutics's investors include Venrock, OrbiMed, Foresite Capital, Pontifax, Cowen Healthcare Investments.
Keros Therapeutics is headquartered in Lexington, United States.
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Keros Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Keros Therapeutics — Funding & Investors." VCBacked, January 3, 2024, https://www.vcbacked.co/company/keros-therapeutics. Accessed October 22, 2026.
VCBacked. (2024). Keros Therapeutics — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/keros-therapeutics
{{cite web |title=Keros Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/keros-therapeutics |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated